AbCellera Biologics Inc. is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody medicines for indications with high unmet medical need. The company operates a vertically integrated platform for antibody drug discovery and development, with specialized capabilities in targeting complex transmembrane proteins such as GPCRs and ion channels, as well as developing multispecific antibodies and T-cell engagers. Its internal pipeline includes ABCL635, a potential first-in-class non-hormonal medicine for moderate-to-severe vasomotor symptoms associated with menopause, and ABCL575, a candidate for atopic dermatitis and other immunology and inflammation conditions. Additional development candidates include ABCL688 for autoimmune conditions and ABCL386 for oncology. The company serves the global pharmaceutical market, with clinical trials currently conducted in Canada. AbCellera maintains a portfolio of downstream stakes and royalties from over 100 historical partner-initiated discovery programs with biopharmaceutical and biotechnology companies. The company completed the construction of a clinical manufacturing facility in Vancouver in 2025 to support its integrated supply chain. Founded by scientists from an academic lab, the company has evolved from a technology partner model to a clinical-stage biotech developing its own drug assets.

Summarised from the company's own disclosures, fiscal year ended Feb 2026

Industry Biotechnology Homepage abcellera.com
Sector Healthcare IR page investors.abcellera.com/overview/default.aspx
Tags
antibody discovery, microfluidics, single-cell analysis, gpcr targeting, t-cell engagers, multispecific antibodies, vasomotor symptoms, atopic dermatitis, autoimmunity, oncology, clinical manufacturing, ABCL635, ABCL575, ABCL688, ABCL386, Trianni
Press page abcellera.com/news

Metrics

Valuation  
Market cap $ 3.697B
Market cap (USD) $ 3.697B
P/E -23.60
PEG —
P/BV 3.48
P/S 54.49
P/OCF -239.62
P/FCF -112.55
Dividend yield —
Turnover / mcap —
Returns  
ROE -14.5%
ROI -14.0%
ROIC -15.6%
Profit margin -194.9%
Growth  
Revenue growing Yes
Profits growing No
Revenue up 3y No
Revenue up 5y No
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding Yes
Buying back stock No
Diluting (TTM) Yes
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 23
Quality score -50.0%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
Revenue 75.128M 28.833M 38.025M 485.424M 375.203M 233.155M
Net profit -146.412M -162.857M -146.398M 158.519M 153.464M 118.918M
Free cash flow -174.067M -186.952M -120.824M 206.7M 186.132M 13.017M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
Share price 3.42 2.93 5.71 10.13 14.3 40.24
Price performance 12m 0.17 -0.49 -0.44 -0.29 -0.64 —

Filed figures

Figure Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (USD) — 903,000 — — 0.00 32M 39.4M
↳ YoY growth +23.2%
↳ 5y CAGR +112.8%
Borrowings, current (USD) — 190,000 — — — — —
Lease liabilities (USD) — 4.39M 40.1M 82.3M 77.4M 65.4M 143M
Cash and deposits (USD) — 594M 476M 387M 133M 156M 129M
Intangible assets (USD) 0.00 115M 148M 132M 120M 42.1M 38.4M
Right-of-use assets (USD) — — — 80.8M 73.1M 66.6M 136M
Net debt (borrowings + leases - cash) (USD) — -590M — — — — —
Cash flow detail
Operating cash flow (USD) 2.69M 22.7M 245M 277M -43.9M -109M -131M
Purchases of property, plant and equipment (USD) -4M -9.67M -58.5M -70.7M -76.9M -78.4M -42.8M
Purchases of intangible assets (USD) — -5M 0.00 -2M -560,000 0.00 —
Change in receivables (cash effect) (USD) -1.8M -5.47M -37.4M -22.7M -45.9M -75.1M -55.6M
Change in payables (cash effect) (USD) — — — -2.09M -15.1M 10.6M 3.46M
Share-based compensation (USD) 890,000 8.4M 30.6M 49.5M 64.2M 67.6M 55.8M
Operating cash flow before change in receivables (USD) 4.5M 28.2M 282M 300M 2.06M -33.4M -75.7M
Free cash flow (OCF - PPE - intangibles) (USD) -1.3M 8.02M 186M 205M -121M -187M -174M
Income detail
Research and development expense (USD) 10.1M 29.4M 62.1M 108M 176M 167M 187M
↳ 5y CAGR +75.3% +44.8%
Total comprehensive income (USD) -2.21M 119M 154M 157M -147M -166M -146M
Comprehensive income to owners (USD) -2.21M 119M 154M 157M -147M -166M -146M
Reported Feb 25, 2022 Feb 25, 2022 Feb 20, 2024 Feb 27, 2025 Feb 27, 2025 Feb 27, 2025 Feb 24, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

AbCellera Reports Q3 2026 Business Results Bull 5 Bear 3 Results

11/9/2026

VANCOUVER, British Columbia--(BUSINESS WIRE)-- AbCellera (Nasdaq: ABCL) today announced financial results for the third quarter of 2026. All financial information in this press release is reported in U.S. dollars, unless otherwise indicated.

“This was a transformative quarter for AbCellera, highlighted by strong clinical execution and balance sheet expansion. Positive top-line Phase 2 results for ABCL635 demonstrated an efficacy and tolerability profile that has potential to redefine the treatment of hot flashes. On the strength of this data, we raised $200 million, bringing our available liquidity to approximately $900 million,” said Carl Hansen, Ph.D., founder and CEO of AbCellera.

October 22, 2026

VANCOUVER, British Columbia--(BUSINESS WIRE)-- AbCellera (Nasdaq: ABCL) announced that the Company will present at the following investor conferences:

  • Stifel Healthcare Conference, November 11, 2026
  • Jefferies Global Healthcare Conference in London, November 16, 2026

A live audio webcast of the presentation may be accessed through a link that will be posted on AbCellera's Investor Relations website . A replay will be available through the same link following the presentation.

About AbCellera Biologics Inc.

AbCellera (Nasdaq: ABCL) is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody-based medicines in the areas of endocrinology, women’s health, immunology, oncology, and more. For more information, please visit www.abcellera.com .

AbCellera Forward-looking Statements

This document contains forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements are based on management’s beliefs and assumptions and on information currently available to management. All statements contained in this document other than statements of historical fact are forward-looking statements, including statements regarding our ability to develop, commercialize and achieve market acceptance of our current and planned products and services, our research and development efforts, and other matters regarding our business strategies, use of capital, results of operations and financial position, plans, objectives for future operations, and the evaluation of our available liquidity to execute on our strategy (including our ability to access our reimbursement based R&D government contributions). The use of certain data derived from cross-study comparisons are not based on any head-to-head clinical trials. Cross-study comparisons are inherently limited and may suggest misleading similarities and differences and are presented for informational purposes. In some cases, you can identify forward-looking statements by the words “may,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “ongoing” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words.

These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. These risks, uncertainties, other factors, and definition of our business metrics are described under “Risk Factors,” “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and elsewhere in the documents we file with the Securities and Exchange Commission from time to time. We caution you that forward-looking statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain. As a result, the forward-looking statements may not prove to be accurate. The forward-looking statements in this document represent our views as of the date hereof. We undertake no obligation to update any forward-looking statements for any reason, except as required by law.

Inquiries
Media: Tiffany Chiu; [email protected] , +1(236)521-6774
Partnering: Murray McCutcheon, Ph.D.; [email protected] , +1(604)559-9005
Investor Relations: Peter Ahn; [email protected] , +1(778)729-9116

Source: AbCellera Biologics Inc.

View All News

Abcellera logo pattern

Quick Links

Investor Email Alerts

Personal Information.

Email Address *Required Email Address is required. Email Address is invalid.

Investor Alert Options *

  • News
  • Quarterly Reports
  • Annual Reports
  • SEC Filings
  • End of Day Stock Quote
  • Events & Presentations

Investor Alert Options is required.

The captcha test has failed. Please try again.

Submit

Unsubscribe

Linkedin logo X/Twitter logo

© 2026 AbCellera Biologics - All rights reserved

Powered By Q4 Inc. 5.191.0.1 (opens in new window)

October 8, 2026

VANCOUVER, British Columbia--(BUSINESS WIRE)-- AbCellera (Nasdaq: ABCL) today announced an upcoming poster presentation of Phase 1/2 data on ABCL635 at The Menopause Society’s (TMS) 2026 Annual Meeting, to be held October 20 to 24 at the Hilton Bayfront in San Diego, California.

Details on AbCellera’s poster presentation at TMS are as follows:

Title: Safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of ABCL635, an NK3R monoclonal antibody antagonist for the treatment of vasomotor symptoms: a Phase 1/2 study
Poster ID: P-92
Date and Time: Thursday, October 22 from 6:15 p.m. to 7:15 p.m. PDT
Location: Indigo Exhibit Hall (Level 2), Hilton Bayfront

AbCellera will present safety, pharmacokinetics, pharmacodynamics, and efficacy data from its Phase 1/2 trial. This includes new safety data from the Phase 1 multiple ascending dose study, as well as new patient-reported outcome data from the Phase 2 study.

About ABCL635

ABCL635 is a potential best-in-class investigational antibody drug for the non-hormonal, long-acting treatment of moderate-to-severe vasomotor symptoms (VMS), commonly known as hot flashes, due to menopause. ABCL635 selectively targets NK3R, a complex transmembrane protein found on hypothalamic KNDy neurons that helps regulate body temperature. ABCL635 is AbCellera’s first program from its GPCR and ion channel platform to advance into the clinic. Additional details are available at www.abcellera.com/pipeline .

The Phase 2 trial of ABCL635 (NCT07118891) is a multicenter, randomized, double-blind, placebo-controlled trial in postmenopausal women with moderate-to-severe VMS due to menopause evaluating safety and efficacy of ABCL635.

About VMS

Hot flashes and night sweats, known as VMS, are the most common menopausal symptoms, impacting up to 80% of women. Many women rate their VMS as moderate to severe, characterized by intense feelings of heat that lead to sweating, chills, and interrupted sleep. VMS are the most frequent reason for seeking medical care for menopause and can persist for over four years after the final menstrual period. VMS have a significant impact on quality of life, are associated with cardiovascular disease risk, and result in lost productivity, career advancement, and income. It is estimated that approximately 12 million women in the US experience moderate-to-severe VMS, of which more than six million seek treatment.

About AbCellera Biologics Inc.

AbCellera (Nasdaq: ABCL) is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody-based medicines in the areas of endocrinology, women’s health, immunology, oncology, and more. For more information, please visit www.abcellera.com .

AbCellera Forward-looking Statements

This document contains forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements are based on management’s beliefs and assumptions and on information currently available to management. All statements contained in this document other than statements of historical fact are forward-looking statements, including statements regarding our ability to develop, commercialize and achieve market acceptance of our current and planned products and services, our research and development efforts, and other matters regarding our business strategies, use of capital, results of operations and financial position, plans, objectives for future operations, and the evaluation of our available liquidity to execute on our strategy (including our ability to access our reimbursement based R&D government contributions). The use of certain data derived from cross-study comparisons are not based on any head-to-head clinical trials. Cross-study comparisons are inherently limited and may suggest misleading similarities and differences and are presented for informational purposes. In some cases, you can identify forward-looking statements by the words “may,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “ongoing” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words.

These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. These risks, uncertainties, other factors, and definition of our business metrics are described under “Risk Factors,” “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and elsewhere in the documents we file with the Securities and Exchange Commission from time to time. We caution you that forward-looking statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain. As a result, the forward-looking statements may not prove to be accurate. The forward-looking statements in this document represent our views as of the date hereof. We undertake no obligation to update any forward-looking statements for any reason, except as required by law.

Inquiries
Media: Tiffany Chiu; [email protected] , +1(236)521-6774
Partnering: Murray McCutcheon, Ph.D.; [email protected] , +1(604)559-9005
Investor Relations: Peter Ahn; [email protected] , +1(778)729-9116

Source: AbCellera Biologics Inc.

View All News

Abcellera logo pattern

Quick Links

Investor Email Alerts

Personal Information.

Email Address *Required Email Address is required. Email Address is invalid.

Investor Alert Options *

  • News
  • Quarterly Reports
  • Annual Reports
  • SEC Filings
  • End of Day Stock Quote
  • Events & Presentations

Investor Alert Options is required.

The captcha test has failed. Please try again.

Submit

Unsubscribe

Linkedin logo X/Twitter logo

© 2026 AbCellera Biologics - All rights reserved

Powered By Q4 Inc. 5.190.1.9 (opens in new window)

Prompts

AbCellera Biologics Inc. (ticker ABCL), listed in United States.

ETFs Holding AbCellera Biologics Inc.

ETF Weight in ETF Shares Market value As of
CPAI 2.07% 971,643 $ 7.627M Jun 30, 2026
AVSC 0.01% 39,660 $ 441.019K Nov 16, 2026
AVUS 0.00% 64,811 $ 720.698K Nov 16, 2026